arrow
M

Michail Vikelis

glyfada headache clinic
H指数:22
被引数:1,463

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness of eptinezumab 300 mg dose escalation in partial responders to 100 mg among patients with difficult-to-treat migraine: A prospective, real-world study by the GRASP study group

在难治性偏头痛患者中,对于对100 mg剂量部分应答者进行300 mg剂量递增的依匹木单抗疗效:GRASP研究小组进行的一项前瞻性、真实世界研究

2026-10-210
PRE
Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group

比较抗CGRP单克隆抗体与托吡酯在偏头痛预防中的疗效与安全性:GRASP研究小组提供的为期六个月、真实世界、意向性治疗回顾性证据

2026-04-050
OAAI
Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study Group

暂停和重新启动Fremanezumab治疗对预防难治性偏头痛的24个月连续治疗效果:GRASP研究组的回顾性、多中心、真实世界数据

2025-08-140
PREAI
Unmet needs in the management of migraine in Greece from the perspective of medical experts: a Delphi consensus (vol 16, 1556808, 2025)

希腊医疗专家视角下偏头痛管理中的未满足需求:一项德尔菲共识(卷 16,1556808,2025)

2025-04-020
OA
The unmet needs in management, the treatment gap and the burden of migraine in Greece: a Delphi consensus and focus group study from patients' perspective

希腊偏头痛的管理未满足需求、治疗差距及疾病负担:一项基于患者视角的德尔菲共识与焦点小组研究

2025-02-240
OA
Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry

更年期及其对fremanezumab预防偏头痛的有效性的影响: 前瞻性,现实世界希腊注册表的事后分析

2024-09-160
PRE
Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints

617偏头痛患者对急性和预防性偏头痛治疗属性和临床试验终点的偏好和看法

2024-06-136
PRE
Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options

对2565名希腊偏头痛患者进行的基于网络的调查结果2023年: 新治疗方案时代的人口统计数据,施加的负担和对急性和预防性治疗的满意度

2024-05-084
OAAI
Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine

连续9个月的Fremanezumab预防对曲坦的反应以及高频发作性偏头痛患者的触发,超敏反应和前驱症状的发生率

2024-01-103
OAAI
Cluster Headache Genomewide Association Study and Meta-Analysis Identifies Eight Loci and Implicates Smoking as Causal Risk Factor

丛集性头痛全基因组关联研究和荟萃分析确定了八个基因座,并暗示吸烟是因果危险因素

2023-08-0721
OA
Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry

Fremanezumab对难以治疗的慢性偏头痛患者的精神病合并症的影响: 前瞻性,多中心,现实世界希腊注册表的事后分析

2023-07-069
OAAI
Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry

至少有三次预防性失败的偏头痛患者对Fremanezumab反应的预测因素: 前瞻性,多中心,现实世界希腊注册表的事后分析

2023-04-299
OAAI